Results
Dukes’ B2 disease, Dukes’ B3 and C disease
MAY, DISEASE
This prospective randomized multi-institutional trial was activated on 20 August 1993 and terminated on 19 May 2000, due to slow accrual. The study stopped disease assessment for all patients in June 2005 (the expected final analysis time for the study per the revised design). Updates, however, have been continuing for survival data. This report is based on data available as of 19 February 2015. By then, the median follow-up time was 15.4 years (range: 0.03–20.3 years) for patients with Dukes’ B3 and C disease. For patients with Dukes’ B2 disease, the median follow-up was 15.8 years (range: 0.02–20.7 years).